Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

Overview

Journal Diseases

Date 2024 May 24

PMID 38785742

Authors

Maurizio Capuozzo

Mariachiara Santorsola

Monica Ianniello

Francesco Ferrara

Andrea Zovi

Nadia Petrillo

Rosa Castiello

Maria Rosaria Fantuz

Alessandro Ottaiano

Giovanni Savarese

Affiliations

Soon will be listed here.

Abstract

Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.

Citing Articles

Medicaid Expansion and Survival Outcomes Among Men With Prostate Cancer.

Akinyemi O, Fasokun M, Hercules E, Ikugbayigbe A, Odusanya E, Hatcher L Cureus. 2025; 17(1):e77434.

PMID: 39822252 PMC: 11735256. DOI: 10.7759/cureus.77434.

References

Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C . Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023; 8(1):450. PMC: 10716479. DOI: 10.1038/s41392-023-01674-3. View

Antonarakis E, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C . Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2019; 38(5):395-405. PMC: 7186583. DOI: 10.1200/JCO.19.01638. View

Mjaess G, Aoun F, Rassy E, Diamand R, Albisinni S, Roumeguere T . Antibody-Drug Conjugates in Prostate Cancer: Where Are we?. Clin Genitourin Cancer. 2022; 21(1):171-174. DOI: 10.1016/j.clgc.2022.07.009. View

Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K . Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023; 24(4):323-334. DOI: 10.1016/S1470-2045(23)00063-3. View

Galsky M, Eisenberger M, Moore-Cooper S, Kelly W, Slovin S, Delacruz A . Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008; 26(13):2147-54. DOI: 10.1200/JCO.2007.15.0532. View

Siebert A, Szymaniak B, Numan Y, Morgans A . Genetically Informed Prostate Cancer Treatment for Metastatic Disease. Urol Clin North Am. 2021; 48(3):365-371. DOI: 10.1016/j.ucl.2021.03.006. View

Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M . Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci. 2021; 22(11). PMC: 8196678. DOI: 10.3390/ijms22115421. View

Das S, Salami S, Spratt D, Kaffenberger S, Jacobs M, Morgan T . Bringing Prostate Cancer Germline Genetics into Clinical Practice. J Urol. 2019; 202(2):223-230. DOI: 10.1097/JU.0000000000000137. View

Gupta K, Kyprianou N . Microbiota and the landscape of the prostate tumor microenvironment. Am J Clin Exp Urol. 2023; 11(5):352-360. PMC: 10628624. View

10.

Gonzalez-Rodriguez M, Ait Edjoudi D, Cordero-Barreal A, Farrag M, Varela-Garcia M, Torrijos-Pulpon C . Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer. Antioxidants (Basel). 2023; 12(12). PMC: 10741130. DOI: 10.3390/antiox12122112. View

11.

Graff J, Beer T, Alumkal J, Slottke R, Redmond W, Thomas G . A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer. 2020; 8(2). PMC: 7333874. DOI: 10.1136/jitc-2020-000642. View

12.

. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355(9214):1491-8. View

13.

Sokolova A, Cheng H . Genetic Testing in Prostate Cancer. Curr Oncol Rep. 2020; 22(1):5. PMC: 10832578. DOI: 10.1007/s11912-020-0863-6. View

14.

Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R . Hereditary prostate cancer - Primetime for genetic testing?. Cancer Treat Rev. 2019; 81:101927. DOI: 10.1016/j.ctrv.2019.101927. View

15.

Fizazi K, Drake C, Beer T, Kwon E, Scher H, Gerritsen W . Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. 2020; 78(6):822-830. PMC: 8428575. DOI: 10.1016/j.eururo.2020.07.032. View

16.

Petrylak D, Loriot Y, Shaffer D, Braiteh F, Powderly J, Harshman L . Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clin Cancer Res. 2021; 27(12):3360-3369. DOI: 10.1158/1078-0432.CCR-20-1981. View

17.

Crabb S, Griffiths G, Dunkley D, Downs N, Ellis M, Radford M . Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial. Eur Urol. 2022; 82(5):512-515. DOI: 10.1016/j.eururo.2022.05.019. View

18.

Mutetwa T, Foulkes W, Polak P . Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(9):890. DOI: 10.1056/NEJMc2023199. View

19.

Capuozzo M, Celotto V, Landi L, Ferrara F, Sabbatino F, Perri F . Beyond Body Size: Adiponectin as a Key Player in Obesity-Driven Cancers. Nutr Cancer. 2023; 75(10):1848-1862. DOI: 10.1080/01635581.2023.2272343. View

20.

Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M . Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021; 22(4). PMC: 7913806. DOI: 10.3390/ijms22041551. View